Results 101 to 110 of about 10,073,743 (132)

Prescribing Trends for Bipolar Disorder Drugs in Alberta, Canada Between 2008 and 2021: Tendances en matière de prescription de médicaments pour le trouble bipolaire en Alberta, au Canada, entre 2008 et 2021. [PDF]

Can J Psychiatry
Shafiq S, Ronksley PE, Elliott MJ, Bulloch AGM, Patten SB.   +4 more
europepmc   +1 more source

QSPR modeling of physicochemical properties of SSRI and SNRI antidepressants using advanced molecular graph descriptors. [PDF]

Sci Rep
Kabeer A, Mufti ZS, Almehizia AA, Assiri AA, Ganati GA.   +4 more
europepmc   +1 more source

Global Trends in the Use of Pharmacotherapy for the Treatment of Bipolar Disorder. [PDF]

Curr Psychiatry Rep
Yocum AK, Singh B.
europepmc   +1 more source

Trajectories of psychotropic drug use patterns in psychiatric inpatients with acute depressive episodes of bipolar disorder: results from a pharmacovigilance program in German-speaking countries from 2007 to 2024. [PDF]

Int J Bipolar Disord
Seifert J, Stübner S, Dabbert D, Greil W, Maier HB, Grohmann R, Toto S.   +6 more
europepmc   +1 more source

Psilocybin and Bipolar Depression: Promise and Prudence. [PDF]

CNS Drugs
Marques MG, Patarroyo-Rodriguez L, Singh B.   +2 more
europepmc   +1 more source

Treatment Selection for Major Depressive Disorder in Veterans Health Administration Outpatients.

JAMA Netw Open
Aslan M, Tylee DS, Chen P, Dai Y, Li Y, Mutalik P, Yan L, Huang X, Polimanti R, Wang Z, Mohamed S.   +10 more
europepmc   +1 more source

Prescription and use of psychoactive medications among cancer patients and associated factors in lower and upper middle-income countries: systematic review. [PDF]

Support Care Cancer
Merabtine T, Gnonlonfoun DD, Marcellaud E, Altayyar S, Tarhini Z, Christou N, Jost J.   +6 more
europepmc   +1 more source

Rosiglitazone Adjunct to Sertraline for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. [PDF]

Depress Anxiety
Shamabadi A, Karami R, Sadati S, Farahmand K, Ershadmanesh M, Moosavi R, Rahiminejad F, Khodaei Ardakani MR, Akhondzadeh S.   +8 more
europepmc   +1 more source

Research advances and future perspectives of nanomaterials for depression therapy: a scientometric review. [PDF]

J Nanobiotechnology
Xu D, Guo C, Li WT, Ding Y, Gao K, Zhang W, Zhao MN, Tao XR, Wang JW.   +8 more
europepmc   +1 more source

Risk of Psychiatric Worsening With GLP-1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression. [PDF]

Diabetes Obes Metab
Chang Y, Hsieh MH, Ju PC, Chang CC.
europepmc   +1 more source